TheracosBio reports data from trial of diabetes therapy

TheracosBio has reported data from a Phase III study that evaluated Brenzavvy (bexagliflozin) tablets as an adjunct to metformin in adults with type 2 diabetes (T2D) mellitus.

The placebo-controlled, randomised, double-blind study assessed the effectiveness and safety of the SGLT2 inhibitor Brenzavvy against placebo.